EUROPEAN FEDERATION OF BIOTECHNOLOGY: EXBO Members

Prof. Dr. Manuel J.T. Carrondo

CEO, IBET
Apartado 12
P-2781-901 Oeiras
Portugal
Tel.: +351 21 4427787/4421173
Fax: +351 21 4421161
E-Mail: mjtc@itqb.unl.pt
Web: www.ibet.pt

Curriculum Vitae

Chemical Engineer, 1971, Univ. Porto; Master of Sciences (1975) and Philosophy Doctor (1979) Environmental Engineering, Imperial College of Science and Technology, U. London; Habilitation, Chemical Engineering (1991), Univ. Nova de Lisboa.

Full Professor, Chemical and Biochemical Engineering, Faculty of Sciences and Technology, Univ. Nova de Lisboa. Founder and earlier president (currently CEO) of IBET - Institute for Experimental and Technological Biology (www.ibet.pt), founder and board member of the Portuguese Academy of Engineering (1998 2001) and board member of the Euro CASE (Council on Applied Science and Engineering) (1998-2001), chairman of the European Society of Animal Cell Technology (ESACT) (1997-2001) and of Medical Biotechnology Section of the European Federation of Biotechnology (EFB) (1999-2001), member and Vice- Chairman of the External Advisory Group "Cell Factory" (Research Directorate General, European Commission) (1998-2002). Meeting Chairman of the ESACT 14th Meeting "Animal Cell Technology: From Vaccines to Genetic Medicine", Vilamoura, 20-24 May 1996 and of the "3rd Recombinant Protein Production Meeting: A comparative view on host physiology", Tavira-Algarve (Portugal), 11-14 November 2004.

Supervised over twenty Ph.D. students (thesis defended) and published over one hundred papers in refereed international journals; Associate-Editor of Journal of Biotechnology, member of the editorial board of Biotechnology and Bioengineering and referee of Biotechnology Progress, Cytotechnology, Applied Microbiology and Biotechnology, Enzyme and Microbial Biotechnology.

Key areas of research interest:

Animal Cell Technology and its application for human and animal health. Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles as vaccination agents and viruses as deliverables for gene therapy and DNA vaccination. cGMP pilot plant scale-up and production development of biopharmaceuticals.

close window